Logo Logo
Help
Contact
Switch Language to German

Oviedo-Salcedo, Tatiana; Wagner, Elias; Campana, Mattia; Gagsteiger, Anna; Strube, Wolfgang; Eichhorn, Peter; Louiset, Marie-Luise; Luykx, Jurjen; de Witte, Lot D.; Kahn, Rene S.; Benros, Michael E.; Falkai, Peter and Hasan, Alkomiet (2021): Cerebrospinal fluid abnormalities in first- and multi-episode schizophrenia-spectrum disorders: impact of clinical and demographical variables. In: Translational Psychiatry, Vol. 11, No. 1, 621

Full text not available from 'Open Access LMU'.

Abstract

Multiple lines of evidence indicate that immunological and inflammatory alterations contribute at least in a subgroup to the pathophysiology of schizophrenia. In this retrospective chart review, we investigated whether clinical factors contribute to altered cerebrospinal fluid (CSF) findings in schizophrenia-spectrum disorders. Clinical data from electronic medical records of patients with psychotic disorders (ICD-10: F20-F29) who received routine CSF diagnostics at the Department of Psychiatry and Psychotherapy, LMU Munich, Germany, were included. Chi(2) tests for dichotomous outcomes and independent t tests for continuous outcomes were used to compare differences between groups. A total of 331 patients were included in the analyses (43.2% female and 56.8% male). The mean age was 37.67 years (+/- 15.58). The mean duration of illness was 71.96 months (+/- 102.59). In all, 40% (128/320) were first-episode psychosis (FEP) patients and 60% (192/320) were multi-episode psychosis (MEP) patients. Elevated CSF protein levels were found in 19.8% and elevated CSF/serum albumin ratios (Q(Alb)) in 29.4% of the cases. Pleocytosis was found in 6.1% of patients. MEP patients showed significantly higher mean Q(Alb) compared with FEP patients (t((304.57)) = -2.75, p = 0.006), which did not remain significant after correcting for age. Q(Alb) elevation occurred more frequently in men (X-(1)(2) = 14.76, p = <0.001). For treatment resistance, family history, and cMRI alterations, no significant differences in CSF-related outcomes were detected. Our work extends other retrospective cohorts confirming a relevant degree of CSF alterations in schizophrenia-spectrum disorders and shows the difficulty to relate these alterations to clinical and disease course trajectories. More research is needed to develop treatment response predictors from CSF analyses.

Actions (login required)

View Item View Item